Prosecution Insights
Last updated: May 29, 2026

Stealth BioTherapeutics Inc.

8 pending office actions • 5 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
5
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
1
Due this week
2
Due this month
2
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 7 days (1)Due ≤ 30 days (2)Due ≤ 60 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (50%)
0
Easy (0%)
4
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only4 (50%)
No statute on record4 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NIEBAUER, RONALD T 2 41.4% +33.8%
GEMBEH, SHIRLEY V 1 63.1% +34.0%
MIKNIS, ZACHARY J 1 68.5% +32.6%
TIEN, LUCY MINYU 1 61.3% +35.6%
OTTON, ALICIA L 1 65.0% +9.0%
KATAKAM, SUDHAKAR 1 75.0% +23.0%
GAMETT, DANIEL C 1 67.6% +28.8%

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18404263 AROMATIC-CATIONIC PEPTIDES AND USES OF SAME MIKNIS, ZACHARY J 67d overdue
18010526 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY GAMETT, DANIEL C 42d overdue
18460346 METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS NIEBAUER, RONALD T 3d overdue
18285570 SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS TIEN, LUCY MINYU 7d
18672743 COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY GEMBEH, SHIRLEY V 20d
18011354 PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES KATAKAM, SUDHAKAR 26d
18620789 METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION NIEBAUER, RONALD T 33d

Top Art Units

Art UnitApps
1658 4
1615 1
1612 1
1699 1
1647 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18672743 COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY GEMBEH, SHIRLEY V 1615 Other Non-Final OA 20d Pending May 23, 2024
18620789 METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION NIEBAUER, RONALD T 1658 Other Final Rejection 33d Pending Mar 28, 2024
18404263 AROMATIC-CATIONIC PEPTIDES AND USES OF SAME MIKNIS, ZACHARY J 1658 §103 Final Rejection 67d overdue Pending Jan 04, 2024
18285570 SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS TIEN, LUCY MINYU 1612 Other Non-Final OA 7d Pending Oct 04, 2023
18460346 METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS NIEBAUER, RONALD T 1658 Other Non-Final OA 3d overdue Pending Sep 01, 2023
18221140 MITOCHONDRIA-TARGETING PEPTIDES OTTON, ALICIA L 1699 §103 Non-Final OA 55d Pending Jul 12, 2023
18011354 PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES KATAKAM, SUDHAKAR 1658 §103 Non-Final OA 26d Pending Dec 19, 2022
18010526 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY GAMETT, DANIEL C 1647 §103 Final Rejection 42d overdue Pending Dec 15, 2022

Managing Stealth BioTherapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month